The Relationship Between Erythrocyte Transfusion and Nutrition and Necrotizing Enterocolitis in Preterm Infants
Investigation of the Relationship Between Erythrocyte Transfusion and Nutrition and Necrotizing Enterocolitis in Preterm Infants: a Randomized Controlled Clinical Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Senem A Özdemir, MD
- Phone Number: 05327614670
- Email: drsenemalkan@yahoo.com
Study Contact Backup
- Name: Şebnem A Çalkavur, MD
- Phone Number: 05327614670
- Email: sebnemcalkavur@yahoo.com
Study Locations
-
-
Izmir
-
İzmirli, Izmir, Turkey, 35210
- Recruiting
- Behcet Uz Children's Hospital
-
Contact:
- Senem A Özdemir, MD
- Phone Number: 5327614670
- Email: drsenemalkan@yahoo.com
-
Contact:
- Senem Alkan Ozdemir, MD
- Phone Number: 05327614670
- Email: drsenemalkan@yahoo.com
-
Sub-Investigator:
- Rüya Çolak, MD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- <32 gestational week and/or <1500 g birth weight
Exclusion Criteria:
- Major congenital anomalies, hemodynamic instability
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Group 1
Control group
|
Intestinal Fatty Acid Binding Protein will be taken from all participants before the tx and after the tx
|
|
Group 2
Feeding will not stop during the transfusion
|
Intestinal Fatty Acid Binding Protein will be taken from all participants before the tx and after the tx
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
necrotizing enterocolitis
Time Frame: 0-48 hours after tx
|
0-48 hours after tx
|
|
|
Mortality
Time Frame: 0-24 hour after tx
|
If all babies die after tx study will be finished
|
0-24 hour after tx
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Chair: Rüya Çolak, MD, Behcet Uz Children's Hospital
Study record dates
Study Major Dates
Study Start (Anticipated)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2019/279
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.